Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Haendler

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
British Journal of Haematology|June 28, 2017
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphomaElena Bernasconi, Eugenio Gaudio, Pascale Lejeune, et al.
Molecular Oncology|January 15, 2024
Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosisTatsuo Sugawara, Ekaterina Nevedomskaya, Simon Heller, et al.
Molecular Cancer Therapeutics|October 5, 2019
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer ModelsAntje M Wengner, Gerhard Siemeister, Ulrich Lücking, et al.
Cellular Oncology (Dordrecht, Netherlands)|January 25, 2021
The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer modelsClara Lemos, Volker K Schulze, Simon J Baumgart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate CancerChristoph A Schatz, Sabine Zitzmann-Kolbe, Ingrid Moen, et al.
Journal of Medicinal Chemistry|April 14, 2017
Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L BromodomainsLéa Bouché, Clara D Christ, Stephan Siegel, et al.
ACS Chemical Biology|August 30, 2017
Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast DifferentiationJulia C Meier, Cynthia Tallant, Oleg Fedorov, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
British Journal of Haematology|June 28, 2017
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphomaElena Bernasconi, Eugenio Gaudio, Pascale Lejeune, et al.
Molecular Oncology|January 15, 2024
Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosisTatsuo Sugawara, Ekaterina Nevedomskaya, Simon Heller, et al.
Molecular Cancer Therapeutics|October 5, 2019
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer ModelsAntje M Wengner, Gerhard Siemeister, Ulrich Lücking, et al.
Cellular Oncology (Dordrecht, Netherlands)|January 25, 2021
The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer modelsClara Lemos, Volker K Schulze, Simon J Baumgart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate CancerChristoph A Schatz, Sabine Zitzmann-Kolbe, Ingrid Moen, et al.
Journal of Medicinal Chemistry|April 14, 2017
Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L BromodomainsLéa Bouché, Clara D Christ, Stephan Siegel, et al.
ACS Chemical Biology|August 30, 2017
Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast DifferentiationJulia C Meier, Cynthia Tallant, Oleg Fedorov, et al.
Pageof 6